Results 41 to 50 of about 2,984,423 (243)

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Dose Effects of Orally Administered Spirulina Suspension on Colonic Microbiota in Healthy Mice

Frontiers in Cellular and Infection Microbiology, 2019
Oral supplemented nutraceuticals derived from food sources are surmised to improve the human health through interaction with the gastrointestinal bacteria.
Jinlu Hu, Yaguang Li, Sepideh Pakpour, Sufang Wang, Zhenhong Pan, Zhenhong Pan, Junhong Liu, Junhong Liu, Qingxia Wei, Qingxia Wei, Junjun She, Huaixing Cang, Rui Xue Zhang, Rui Xue Zhang, Rui Xue Zhang   +14 more
doaj   +1 more source

Study on orally delivered paclitaxel nanocrystals: modification, characterization and activity in the gastrointestinal tract [PDF]

Royal Society Open Science, 2017
Drug nanocrystals (NCs) can improve the solubility and bioavailability of insoluble drugs for oral administration. However, the biocompatibility and mechanisms of transmittance of drug NCs through the intestinal epithelial tissue are still not well ...
Runcong Liu, Ya-Nan Chang, Gengmei Xing, Min Li, Yuliang Zhao   +4 more
doaj   +1 more source

Oral Delivery of Biologics via the Intestine

, 2020
Biologics are currently one of the most promising avenues for therapeutic interventions in conditions such as metabolic disease, ageing and inflammatory disorders, and for chronic ailments, oral delivery of such medicines has for years been recognised as
Roger New
core   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration

Pharmaceutics
Diabetes is a global disease that can lead to a range of complications. Currently, the treatment of type 2 diabetes focuses on oral hypoglycemic drugs and insulin analogues. Studies have shown that drugs such as oral metformin are useful in the treatment
Xinxin Yang, Ruiting Lin, Changzhuo Feng, Qiyuan Kang, Peng Yu, Yongzhi Deng, Ye Jin   +6 more
doaj   +1 more source

Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide

Pharmaceutics, 2019
Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in ...
Muhammad Mustafa Abeer, Anand Kumar Meka, Naisarg Pujara, Tushar Kumeria, Ekaterina Strounina, Rute Nunes, Ana Costa, Bruno Sarmento, Sumaira Z. Hasnain, Benjamin P. Ross, Amirali Popat   +10 more
doaj   +1 more source